Evidence map›Paper›PMID 41800094›Full record

ArticleFrontiers in pharmacology2026

DPYD genotyping in patients receiving capecitabine: an exploratory analysis from the D-TORCH study.

Hemavathi Baskarane, Mohit Kumar Divakar, Akhil P Santhosh, Kriti Pallavi, Vishakha Hooda, Vamsi Krishna Yenamandra, Saran Kumar, Vrajesh Shetty, Jahnavi Banotra, Ishaan Gupta and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Hemavathi Baskarane *Department of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Mohit Kumar Divakar *Department of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Akhil P SanthoshDepartment of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Kriti PallaviDepartment of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Vishakha HoodaDepartment of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Vamsi Krishna YenamandraIndian Institute of Science, Bengaluru, India.
Saran KumarIndian Institute of Technology, Delhi, India.
Vrajesh ShettyDepartment of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Jahnavi BanotraDepartment of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Ishaan GuptaIndian Institute of Technology, Delhi, India.
Shilpi MinochaIndian Institute of Technology, Delhi, India.
Pranay TanwarDepartment of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Atul SharmaDepartment of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Payal VasudevaDepartment of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Akash KumarNational Cancer Institute, Jhajjar, India.
R ChethanDepartment of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Sameer BakhshiDepartment of Medical Oncology, All India Institute of Medical Science, New Delhi, India.
Atul BatraDepartment of Medical Oncology, All India Institute of Medical Science, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancer genomicscapecitabine toxicityDPYD gene polymorphismD-TORCH trialpharmacogenomics (PGx)pharmacogentics

Identifiers

PMID41800094
PMCPMC12963234

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.